Anixa Biosciences, Inc.

Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
    • COVID-19
      • Introduction
      • Science
      • Collaborators
  • Pipeline
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
  • Careers
  • Contact Us

SEC Filings

Investors

Investors

  • Overview
  • News Releases
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR
    • RSS News Feed
  • SEC Filings

  • Overview
Filter Filings:
Date Form Description Docs XBRL Pages
03/27/18 424B5 Prospectus filed pursuant to Rule 424(b)(5) 35
03/09/18 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.2
EX-32.2
31
03/05/18 8-K Current report filing
Related Documents
EX-99.1
4
02/15/18 CT ORDER Confidential treatment order 1
02/15/18 SC 13D Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities 6
02/14/18 S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Related Documents
EX-5.1
EX-1
37
02/12/18 DEF 14A Definitive proxy statements 36
01/30/18 SC 13G/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions 14
01/30/18 SC 13G/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions 14
01/26/18 PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition 36
RSS
  • << Previous
  • 1...
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • ...79
  • Next >>

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Mar 4, 2021

Anixa Biosciences Announces European Patent Issued for its CAR-T Cancer Therapy

Read More...
Feb 25, 2021

Anixa Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference

Read More...
Feb 16, 2021

Anixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates

Read More...
Copyrights © 2021 Anixa Biosciences, Inc.. All Rights Reserved.
Privacy Policy Disclaimer Sitemap